ABEONA THERAPEUTICS INC.
Company Stats
- Market Cap
- $300.2M
- as of Sep 30, 2026
- Enterprise Value
- $241.8M
- Shares Outstanding
- 57.2M
- Free Float
- 56.3%
Income Statement
- Revenue
- $5.8M
- Operating Income
- -$89.4M
- Net Income
- $71.2M
- EBITDA
- -$86.9M
- Revenue Growth, 3Y
- 60.3%
Cash Flow
- Free Cash Flow
- -$84.3M
- FCF Yield
- -28.1%
- Owner FCF Yield
- -31.7%
Balance Sheet
- Cash & Equivalents
- $78.4M
- Total Debt
- $20.0M
- Net Cash
- $58.4M
Returns & Capital
- SBC, 3Y Avg
- $7.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $5.8M | -$84.3M | -1448.5% |
| FY2024 | — | -$58.5M | — |
| FY2023 | $3.5M | -$37.3M | -1066.9% |
| FY2022 | $1.4M | -$43.6M | -3084.4% |
| FY2021 | $3.0M | -$69.8M | -2327.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 20, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Abeona to Buy APT-1011 in $20 Million Equity Deal
Stronger demand supports expansion as pricing diverges